Elan veterans grab $34m for neurodegenerative diseases

The only two employees at the virtual biotechnology company Annexon Biosciences are former Elan Pharmaceuticals business and research executives Doug Love and Ted Yednock, but they raised $34m in a Series A-1 venture capital funding round to advance drugs for neurodegenerative diseases.